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Plasma tau in Alzheimer disease
ABSTRACT
Objective: To test whether plasma tau is altered in Alzheimer disease (AD) and whether it is
related to changes in cognition, CSF biomarkers of AD pathology (including b-amyloid [Ab] and
tau), brain atrophy, and brain metabolism.
Methods: This was a study of plasma tau in prospectively followed patients with AD (n 5 179),
patients with mild cognitive impairment (n 5 195), and cognitive healthy controls (n 5 189) from
the Alzheimer’s Disease Neuroimaging Initiative (ADNI) and cross-sectionally studied patients
with AD (n 5 61), mild cognitive impairment (n 5 212), and subjective cognitive decline (n 5
174) and controls (n 5 274) from the Biomarkers for Identifying Neurodegenerative Disorders
Early and Reliably (BioFINDER) study at Lund University, Sweden. A total of 1284 participants
were studied. Associations were tested between plasma tau and diagnosis, CSF biomarkers, MRI
measures, 18fluorodeoxyglucose-PET, and cognition.
Results: Higher plasma tau was associated with AD dementia, higher CSF tau, and lower CSF
Ab42, but the correlations were weak and differed between ADNI and BioFINDER. Longitudinal
analysis in ADNI showed significant associations between plasma tau and worse cognition, more
atrophy, and more hypometabolism during follow-up.
Conclusions: Plasma tau partly reflects AD pathology, but the overlap between normal aging and
AD is large, especially in patients without dementia. Despite group-level differences, these re-
sults do not support plasma tau as an AD biomarker in individual people. Future studies may test
longitudinal plasma tau measurements in AD. Neurology® 2016;87:1827–1835
GLOSSARY
Ab5 b-amyloid; AD 5 Alzheimer disease; ADAS 5 Alzheimer’s Disease Assessment Scale–Cognitive subscale; ADNI 5
Alzheimer’s Disease Neuroimaging Initiative; BioFINDER 5 Biomarkers for Identifying Neurodegenerative Disorders
Early and Reliably; CI 5 confidence interval; CN 5 cognitively healthy control; DSM-III-R 5 Diagnostic and Statistical
Manual of Mental Disorders, 3rd Edition, Revised; EPIC 5 European Prospective Investigation Into Cancer and Nutri-
tion; FDG 5 18fluorodeoxyglucose; MCI 5 mild cognitive impairment; MMSE 5Mini-Mental State Examination; P-tau 5
phosphorylated tau; T-tau 5 total tau.
Brain accumulation of b-amyloid (Ab) and phosphorylated tau (P-tau) in Alzheimer disease
(AD) may be monitored by CSF and PET biomarkers.1 These technologies have revolu-
tionized clinical research and trials and are rapidly transforming clinical practice.2 However,
they are hampered by their relative invasiveness and high costs. There is a great unmet need
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for less invasive and cheaper biomarkers of
AD pathology. Plasma tau is a candidate
because tau is a brain-specific protein that
may be expected to leak from brain intersti-
tial fluid to the plasma compartment in AD.
Most studies of plasma tau in AD have
been small, including up to z150 partici-
pants,3–8 with one study including 273 par-
ticipants.9 The results have been contradictory,
showing clearly elevated levels in AD
(several studies from one group3,6,8), mild
elevations in AD,7 no difference between
patients with AD and controls,9 or reduced
levels in AD.4,5
To clarify the role of plasma tau in AD, we
used an ultrasensitive digital ELISA method in
2 large cohorts with 563 participants from
a prospective North American study and 721
participants from a cross-sectional Swedish
study. We tested the hypotheses that plasma
tau is elevated in AD dementia, correlates with
reduced CSF Ab42 and increased CSF total
tau (T-tau) and P-tau (biomarkers of AD
pathology), and correlates with cognitive
impairment, brain atrophy, and reduced brain
metabolism.
METHODS ADNI study design. As noted on the Alz-
heimer’s Disease Neuroimaging Initiative (ADNI) database,
“Data were obtained from the Alzheimer’s Disease Neuroi-
maging Initiative (ADNI) database (adni.loni.usc.edu). The
ADNI was launched in 2003 as a public-private partnership,
led by Principal Investigator Michael W. Weiner, MD. For
up-to-date information, see www.adni-info.org” (http://adni.
loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_DSP_
Policy.pdf). ADNI participants have been recruited from .50
sites across the United States and Canada. For the current
study, we used data accessed at the ADNI database on
November 11, 2015.
ADNI participants. Our ADNI cohort consisted of all cogni-
tively healthy controls (CNs), patients with mild cognitive
impairment (MCI), and patients with AD dementia with
available baseline plasma tau samples from ADNI-1.
Inclusion and exclusion criteria were described in detail
previously.10 Briefly, all ADNI-1 participants were between
the ages of 55 and 90 years, had completed at least 6 years
of education, were fluent in Spanish or English, and had no
significant neurologic disease other than AD. CNs had a Mini-
Mental State Examination (MMSE) score $24 and Clinical
Dementia Rating score of 0. Patients with MCI had an MMSE
score $24, objective memory loss tested by delayed recall of
the Wechsler Memory Scale Logical Memory II (.1 SD below
the normal mean), a Clinical Dementia Rating score of 0.5,
preserved activities of daily living, and absence of dementia.
Patients with AD dementia fulfilled the National Institute of
Neurologic and Communicative Disorders and Stroke and the
Alzheimer’s Disease and Related Disorders Association criteria
for probable AD11 and had an MMSE score of 20 to 26 and
Clinical Dementia Rating score of 0.5–1.0.
ADNI measurements. Several of the ADNI procedures have
been described previously.12,13 CSF Ab42, T-tau, and P-tau were
measured with the multiplex xMAP Luminex platform
(Luminex Corp, Austin, TX) with the INNOBIA AlzBio3 kit
(Fujirebio, Ghent, Belgium). Participants were classified as Ab-
positive or -negative with the use of a previously established
cutoff (CSF Ab42 ,192 pg/mL).13 Using this cutoff, we
excluded 9 patients with AD dementia who were Ab-negative
and therefore likely misdiagnosed. Cognition was assessed by
MMSE and Alzheimer’s Disease Assessment Scale–Cognitive
subscale (ADAS-cog; at screening and 6, 12, 18, 24, 36, and
48 months; n: CNs, 189, 181, 175, 0, 168, 157, and 102; MCI,
195, 188, 182, 167, 154, 130, and 68; AD, 179, 167, 151, 4,
131, 12, and 3). Structural brain images were acquired with
1.5T MRI scanners (at screening and 6, 12, 18, 24, 36 and 48
months; n: CNs, 193, 176, 164, 0, 150, 125, and 86; MCI, 195,
180, 169, 151, 133, 96, and 54; AD, 177, 156, 136, 1, 101, 2,
and 1) with T1-weighted MRI scans using a sagittal volumetric
magnetization prepared rapid gradient echo sequence.14
FreeSurfer was used for quantification of volumes.14 Right and
left hippocampi were averaged. 18Fluorodeoxyglucose (FDG)-
PET image data were acquired (at screening and 6, 12, 18, 24,
36 and 48 months; n: CNs, 86, 80, 73, 0, 71, 61, and 51; MCI,
96, 90, 88, 80, 72, 57, and 29; AD, 91, 83, 71, 1, 55, 1, and 1)
as described previously.15 For FDG-PET, we averaged counts of
the lateral and medial frontal, anterior, and posterior cingulate,
lateral parietal, and lateral temporal regions. The data were
obtained from 2005 to 2014.
BioFINDER study design, participants, and
measurements. From the Swedish 4-center Biomarkers for
Identifying Neurodegenerative Disorders Early and Reliably
(BioFINDER) study, we included CNs, patients without
dementia with mild cognitive symptoms characterized as
having subjective cognitive decline or MCI, and patients with
AD dementia. Inclusion/exclusion criteria have been described
elsewhere.16,17 CNs were originally enrolled from the
population-based European Prospective Investigation Into
Cancer and Nutrition (EPIC) cohort.18 The inclusion criteria
were age $60 years, MMSE score of 28 to 30, and fluent in
Swedish. Exclusion criteria were the presence of subjective
cognitive impairment, significant neurologic or psychiatric
disease, dementia, or MCI. Patients with subjective cognitive
decline and MCI were recruited consecutively and were
assessed by physicians with special competence in dementia
disorders. The inclusion criteria were as follows: referred to the
memory clinics because of cognitive impairment, not fulfilling
the criteria for dementia, MMSE score of 24 to 30, age of 60 to
80 years, and fluent in Swedish. The exclusion criteria were
cognitive impairment that without doubt could be explained
by another condition (other than prodromal dementia), severe
somatic disease, and refusing lumbar puncture or
neuropsychological investigation. The classification was based
on a neuropsychological battery and the assessment of a senior
neuropsychologist. Patients with a clinical syndrome of AD
dementia met the DSM-III-R criteria for dementia19 and the
National Institute of Neurologic and Communicative
Disorders and Stroke and the Alzheimer’s Disease and Related
Disorders Association criteria for AD.11 All participants
with plasma tau data were included. CSF sampling was
done at baseline, following the Alzheimer’s Association
Flow Chart.20 CSF samples were analyzed by ELISAs
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(INNOTEST, Fujirebio, Gent, Belgium, for Ab42 and P-tau;
and ADx, EUROIMMUN, Luebeck, Germany, for T-tau). The
data were obtained from 2009 to 2015.
Plasma tau measurements. Plasma tau was analyzed with the
Human Total Tau kit (research use only grade, Quanterix, Lex-
ington, MA) on the Simoa HD-1 analyzer (CE marker). This is
an updated version of the assay described previously21 that uses
a monoclonal capture antibody that reacts with a linear epitope in
the midregion of all tau isoforms and a detection antibody that
reacts with a linear epitope in the N-terminal region of T-tau.
The same method (2 different lots) was used for BioFINDER and
ADNI. ADNI samples were analyzed at the Clinical
Neurochemistry Laboratory, Sahlgrenska University Hospital,
Mölndal, Sweden, and BioFINDER samples were analyzed at
Quanterix.
Plasma tau was higher in BioFINDER (mean 5.53 ng/L, SD
2.99 ng/L, median 5.11 ng/L, interquartile range 3.78–6.57 ng/
L) than in ADNI samples (mean 2.80 ng/L, SD 1.35 ng/L,
median 2.65 ng/L, interquartile range 1.88–3.44 ng/L). Three
ADNI participants (1 CN and 2MCI; plasma tau.10 ng/L) and
one BioFINDER participant (CN; plasma tau 48.7 ng/L) were
extreme outliers and were excluded from all analyses. BioFIND-
ER samples had undergone slightly different sample handling
than ADNI samples with one less freeze-thaw cycle.
Statistical analysis. First, we tested associations between plasma
tau and demographic factors using Mann-Whitney U and
Spearman correlation. Second, we tested associations between
plasma tau and diagnosis using linear regression adjusted for
confounders (with plasma tau as outcome). Third, we tested
associations between plasma tau and CSF biomarkers using
linear regression adjusted for confounders (with plasma tau as
predictor). Fourth, we tested associations between plasma tau
and cognition, brain structure, and brain metabolism with
longitudinal data using linear mixed-effects models. These
models had random intercepts and slopes for time and an
unstructured covariance matrix for the random effects and
included the interaction between (continuous) time and plasma
tau as predictor with adjustment for confounders. To test whether
variables were related to study dropout (missing data for
cognition, MRI and FDG-PET), we used a generalized mixed-
effects model with a binomial response, with plasma tau as
predictor of missing data (a missing indicator, true/false, for
each study visit). We evaluated interactions between predictors
and diagnosis. If they were significant, we performed subgroup
analyses within diagnostic groups.
All continuous outcome variables were standardized to
facilitate comparisons between modalities. Beta coefficients
(which are presented with 95% confidence intervals [CIs])
from linear regressions and linear mixed effects therefore
refer to standardized effects (b 5 1 implies that a 1-ng/L
increase in plasma tau was associated with a 1-SD increase
in the dependent variable).
We checked model assumptions by inspecting residuals
(normality, histograms, q-q plots, linearity, heteroscedasticity,
leverage, influence, correlations with fitted values, and predic-
tors of interest). For linear mixed-effects models, we evaluated
marginal residuals and conditional residuals. All tests were 2
sided. Significance was determined at p , 0.05. All statistics
were done with R (version 3.2.3, The R Foundation for Sta-
tistical Computing).
Standard protocol approvals, registrations, and patient
consents. Regional ethics committees of all institutions
approved the ADNI study. The Regional Ethics Committee in
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Lund, Sweden, approved the BioFINDER study. All study partic-
ipants gave written informed consent.
RESULTS Table 1 provides demographics. High
plasma tau was associated with missing data for
MMSE (p 5 0.0017), ADAS-cog (p 5 0.00047),
and MRI (p 5 0.036). This was driven by the
patients with AD dementia, who had high
plasma tau levels and shorter follow-up than the
other groups (see above). The effects of plasma tau
on longitudinal cognition and volume may
therefore be slightly underestimated, although
mixed-effect models are robust to missing data
associated with covariates.22
Plasma tau and demographic factors. Plasma tau did not
correlate with age (ADNI: r 5 0.042, p 5 0.32;
BioFINDER: r 5 20.012, p 5 0.74), sex (ADNI:
median 2.67 ng/L for men vs 2.64 ng/L for women,
p 5 0.51; BioFINDER: 4.95 ng/L for men vs
5.24 ng/L for women, p 5 0.16) or education (AD-
NI: r 5 20.067, p 5 0.11; BioFINDER: r 5
20.044, p5 0.24). Plasma tau was slightly increased
in APOE e4 carriers compared with noncarriers in
ADNI (2.75 vs 2.55 ng/L, p 5 0.022) but not in
BioFINDER (5.10 vs 5.11 ng/L, p 5 0.70).
Plasma tau in different diagnostic groups. In ADNI,
plasma tau was higher in patients with AD dementia
(figure 1A) compared with CNs and patients with
MCI. In contrast, plasma tau did not differ between
patients with MCI and CNs (b 5 20.11, 95% CI
20.38 to 0.17, p 5 0.44) or between patients with
progressive MCI (diagnosed with AD dementia dur-
ing the 9-year follow-up, n 5 105) and CNs (b 5
20.12, 95% CI 20.42 to 0.17, p 5 0.41; results
from a model restricted to progressive participants
with MCI and CNs). All comparisons were done
with linear regressions adjusted for APOE e4, age,
and sex.
Plasma tau and biomarkers of Ab pathology. High
plasma tau correlated weakly with low CSF Ab42 in
ADNI (figure 1B, table 2). There was no interaction
between plasma tau and diagnosis of CSF Ab42; thus,
we did not test effects within diagnostic groups.
However, in the whole study cohort, we compared
Figure 1 Plasma tau, diagnosis, and CSF b-amyloid-42 (Ab42)
Baseline data from the Alzheimer’s Disease Neuroimaging Initiative (ADNI). (A) Plasma tau
and diagnosis. p Values from a linear regression model with plasma tau as the dependent
variable and diagnosis as a categorical predictor, adjusted for APOE e4, age, and sex. Cog-
nitively healthy controls (CNs) had lower levels than patients with Alzheimer disease (AD; b5
20.48, 95% confidence interval [CI]20.19 to 0.78), and patients with mild cognitive impair-
ment (MCI) had lower levels than patients with AD (b 5 20.38, 95% CI 20.65 to 0.098). (B)
Plasma tau and CSF Ab42. The trend line is from a linear regression model with plasma tau as
the dependent variable and CSF Ab42 as the predictor, adjusted for diagnosis, APOE e4, age,
and sex. The shaded area indicates the 95% CI. In a sensitivity analysis, we removed the 2
bottom-right observations. This affected the slope, but plasma tau and CSF Ab42 were still
correlated (b 5 23.99, 95% CI 27.68 to 0.30, p 5 0.034 compared to b 5 24.86, 95% CI
28.38 to 1.33, p 5 0.0071 with all observations included). The b coefficients are on the
original scale of CSF Ab42; see table 2 for coefficients using standardized data. (C) Plasma
tau in diagnostic groups stratified by CSF Ab42 (Ab-positive, CSF Ab42 ,192 ng/L, closed
circles; Ab-negative, CSF Ab42 .192 ng/L, open circles). p Values from a linear regression
model testing the effect of the combination of diagnostic
group and Ab status to predict plasma tau, adjusted for
APOE e4, age, and sex. Patients with AD had higher plasma
tau levels than Ab-negative CNs (b 5 0.62, 95% CI 1.07–
0.17), Ab-positive CNs (b 5 0.67, 95% CI 1.16–0.18), Ab-
negative patients with MCI (b5 0.90, 95% CI 1.37 – 0.42),
and Ab-positive patients with MCI (b5 0.43, 95% CI 0.78–
0.081), and Ab-positive patients with MCI had higher
plasma tau levels than Ab-negative patients with MCI (b 5
0.47, 95% CI 0.90–0.031).
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plasma tau between diagnostic groups stratified by
Ab, comparing Ab-negative and -positive CNs, Ab-
negative and -positive patients with MCI, and Ab-
positive patients with AD (all participants tested
simultaneously by linear regression adjusted for
APOE e4, age, and sex). Patients with AD dementia
had higher plasma tau than all other groups, and Ab-
positive patients with MCI had higher plasma tau
than Ab-negative patients with MCI (figure 1C).
Plasma tau and biomarkers of brain tau pathology.
Plasma tau did not correlate significantly with CSF
T-tau or CSF P-tau in ADNI (table 2). We tested
the interactions for plasma tau by diagnostic group.
There was a borderline significance for CSF P-tau,
which indicated a possible difference between CNs
and patients with MCI for the association between
plasma tau and CSF P-tau (p5 0.056). In a subgroup
analysis, which should be regarded as exploratory, we
found associations in the MCI group between plasma
tau and CSF T-tau (b5 0.12, 95% CI 0.0089–0.24,
p 5 0.035) and CSF P-tau (b 5 0.13, 95% CI
0.016–0.25, p 5 0.025).
Plasma tau and cognition, atrophy, and brain metabolism.
Associations between plasma tau and MMSE score,
ADAS-cog, ventricular volume, hippocampal
volume, and FDG-PET in ADNI are presented in
table 2 and figure 2. High plasma tau was associated
with accelerated decline of MMSE score, high (poor)
baseline ADAS-cog and accelerated increase, large
baseline ventricular volume and accelerated increase,
accelerated decrease of hippocampal volume, and
accelerated decline of FDG-PET. Interactions for
plasma tau by diagnostic group were significant for
MMSE, ADAS-cog, and ventricular volume. We
therefore tested models within diagnostic groups for
these outcomes. High plasma tau was associated with
low baseline MMSE score in AD (b520.062, 95%
CI 20.11 to 0.019, p 5 0.0055) and accelerated
decline of MMSE score in MCI (b 5 20.063,
95% CI 20.11 to 0.018, p 5 0.0068), high
baseline ADAS-cog (b 5 0.82, 95% CI 0.24–1.40,
p5 0.0059) and accelerated increase of ADAS-cog in
AD (b5 0.81, 95% CI 0.28–1.35, p5 0.0031), and
accelerated increase of ventricular volume in AD (b5
0.026, 95% CI 0.013–0.040, p , 0.001). All linear
mixed-effects models were adjusted for diagnosis,
education, age, sex, and APOE e4.
Plasma tau in the BioFINDER cohort. In BioFINDER,
plasma tau did not vary by diagnosis (p 5 0.16–0.83
for comparisons between different groups) or CSF
Ab42 (p 5 0.89) but correlated with CSF T-tau
and P-tau (b 5 0.039, 95% CI 0.013–0.065, p 5
0.0033; and b5 0.032, 95% CI 0.0054–0.059, p5
0.019; figure 3). To determine whether the associa-
tions between plasma tau and CSF biomarkers dif-
fered by diagnostic group, we tested the interaction
between plasma tau and diagnosis, which was present
for AD and CSF T-tau (p 5 0.0051), and there was
a tendency for an association between AD and CSF
P-tau (p 5 0.051). This indicated that the relation-
ship between plasma tau and CSF tau biomarkers
differed between CNs and AD, and we found associ-
ations only in AD dementia (CSF T-tau, b 5 0.13,
95% CI 0.039–0.22, p 5 0.0057; CSF P-tau, b 5
0.093, 95% CI 0.00058–0.19, p 5 0.049). Plasma
tau was not associated with MMSE score (p 5 0.77).
Models were adjusted for age, sex, APOE e4, diagno-
sis, and (for MMSE) education.
DISCUSSION We evaluated an ultrasensitive
method for tau in plasma and found several associa-
tions supporting that plasma tau partly reflects brain
pathology. High plasma tau was found in patients
with AD dementia compared to CNs and patients
with MCI (in ADNI), was associated with low CSF
Ab42 (in ADNI), was associated with high CSF tau
biomarkers (in BioFINDER), was found in APOE e4
carriers (in ADNI), and was associated with poor
cognition at baseline and accelerated worsening of
cognition (in ADNI), large ventricular volumes at
baseline and accelerated atrophy (in ADNI), and
accelerated decrease in cortical glucose metabolism
Table 2 Associations between plasma tau and Alzheimer disease hallmarks in
the Alzheimer’s Disease Neuroimaging Initiative
Outcome b Coefficient (95% CI) p Value
CSF Ab42 20.087 (20.15 to 20.024) 0.0071
CSF T-tau 0.063 (20.0092 to 0.14) 0.087
CSF P-tau 0.047 (20.025 to 0.12) 0.20
MMSE BL 20.017 (20.041 to 0.0063) 0.15
MMSE L 20.063 (20.090 to 20.037) ,0.001
ADAS-cog BL 0.064 (0.034 to 0.094) ,0.001
ADAS-cog L 0.060 (0.035 to 0.085) ,0.001
Ventricular volume BL 0.059 (0.0074 to 0.11) 0.027
Ventricular volume L 0.018 (0.010 to 0.025) ,0.001
Hippocampal volume BL 0.0035 (20.039 to 0.046) 0.87
Hippocampal volume L 20.0063 (20.013 to 20.000047) 0.049
FDG-PET BL 20.016 (20.081 to 0.049) 0.63
FDG-PET L 20.039 (20.060 to 20.019) ,0.001
Abbreviations: Ab42 5 b-amyloid-42; ADAS-cog 5 Alzheimer’s Disease Assessment Scale–
Cognitive subscale; BL 5 baseline; CI 5 confidence interval; FDG 5 18fluorodeoxyglucose;
L 5 longitudinal; P-tau 5 phosphorylated tau; T-tau 5 total tau.
Results are for linear regression (CSF Ab42, CSF T-tau, and CSF P-tau) and linear mixed-
effects models (MMSE, ADAS-cog, ventricular volume, hippocampal volume, FDG-PET).
Plasma tau was the predictor, adjusted for age, sex, diagnostic group, APOE e4, and
education plus intracranial volume (for ventricular and hippocampal volume). All outcome
measures are standardized to facilitate comparison between estimates.
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(in ADNI). No associations were seen in unexpected
or illogical directions. The results suggest that plasma
tau partly reflects AD pathology, but the mild asso-
ciations and the varying results between the cohorts
suggest that plasma tau alone is insufficient as an AD
biomarker. This is different from CSF tau, which has
high diagnostic accuracy for AD.23
Patients with AD had increased plasma tau in AD-
NI, but this was not replicated in BioFINDER. The
small increase in patients with AD was similar to that
in a previous study on another cohort,7 while other
studies failed to detect differences between CNs, pa-
tients with MCI, and patients with AD9 or found
reduced plasma tau in patients with AD compared
with CNs, patients with MCI,4 or those with vascular
dementia.5 One group used an immunomagnetic
reduction assay for plasma tau8 with high separation
between CNs and patients with AD (sensitivity and
specificity .90%3,6,8). Those findings await replica-
tion by independent groups.
Plasma tau was associated with CSF biomarkers of
Ab and tau. The associations were weak and differed
between ADNI and BioFINDER. In ADNI, high
plasma tau was associated with low CSF Ab42, and
patients with AD had higher plasma tau than all other
groups, including Ab-positive patients with MCI,
who had higher plasma tau than Ab-negative patients
with MCI. The association with Ab was not seen in
BioFINDER, in which high plasma tau was instead
associated with slightly increased CSF T-tau and
P-tau. In ADNI, there was a tendency for an associ-
ation between plasma tau and CSF T-tau. Together,
Figure 2 Plasma tau and cognition, MRI volumes, and 18fluorodeoxyglucose (FDG)-PET
Longitudinal data from the Alzheimer’s Disease Neuroimaging Initiative (ADNI). Plasma tau was associated with significantly greater decline of Mini-Mental
State Examination (MMSE) over time (A), lower Alzheimer’s Disease Assessment Scale–Cognitive subscale (ADAS-cog) at baseline and greater increase in
ADAS-cog over time (B; y axis reversed to facilitate comparisons), slightly greater decline of hippocampal volume over time (C), greater ventricular volume at
baseline and greater increase in ventricular volume over time (D; y axis reversed to facilitate comparisons), and greater decline in FDG-PET over time (E). The
error bars are 95% confidence intervals of the mean effects. All measures were standardized to facilitate comparisons between modalities. All results are
from linear mixed-effects models, adjusted for diagnosis,APOE e4, education, age, sex, and (for hippocampus and ventricles) intracranial volume. Plasma tau
was used as a continuous predictor, but for visualization purposes, the graphs show results for quartiles (Q1, plasma tau,1.88 ng/L; Q2, plasma tau,2.65
ng/L; Q3, plasma tau ,3.44 ng/L; Q4, plasma tau ,8.89 ng/L).
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these findings suggest that plasma tau captures some
information about AD pathology. Previous smaller
studies failed to find associations between plasma
tau and CSF tau7 or PET Ab biomarkers.6
High plasma tau was associated with cognitive
impairment, brain atrophy, and brain hypometabo-
lism in ADNI. The associations were significant at
baseline (for ADAS-cog and ventricular volume)
and over time (for MMSE, ADAS-cog, hippocampal
volume, ventricular volume, and FDG-PET) and
were seen mainly in AD and MCI. This suggests that
elevated plasma tau is related to disease activity partic-
ularly in late clinical stages. Few studies have reported
these analyses for plasma tau. One study using the
immunomagnetic reduction assay found associations
between high plasma tau and small volume of gray
matter, hippocampus, and amygdala, but it is not
clear if those associations were corrected for diagnos-
tic group.3
This study is the largest published on plasma
tau, but it is not without limitations. ADNI and
BioFINDER samples were handled with different
protocols and analyzed at different laboratories
with different kit lots, which may have contributed
to the varying results. Some ADNI participants
had plasma tau below the lower limit of quantifica-
tion of the assay (14 CNs, 11 patients with MCI,
10 patients with AD). These measurements are
uncertain but they were included because exclud-
ing them would have biased the data toward higher
plasma tau (excluding them did not change the
main results, data not shown). Another limitation
is that we used only one plasma tau assay. It is pos-
sible that other assays capture tau fragments that
are less sensitive to peripheral degradation and
more likely to reflect AD pathology. A final limita-
tion is that we did not covary for copathologies
that may affect plasma tau levels.
We found associations between elevated plasma
tau and AD hallmarks, but the associations were
mild and differed between cohorts. Our longitudi-
nal data suggest that high plasma tau is associated
with rapid progression in later disease stages. The
large study sample supports generalization of these
results. Future studies should include longitudinal
measurements to explore whether plasma tau is
sensitive to intraindividual changes during the
progression of AD and an assessment of plasma
tau across neurodegenerative diseases. This would
increase the usability of plasma tau as an AD bio-
marker, particularly in clinical trials for patient
enrichment and stratification.
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